Last reviewed · How we verify
Cisplatin / Oxaliplatin
Cisplatin and oxaliplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and triggering cancer cell death.
Cisplatin and oxaliplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and triggering cancer cell death. Used for Colorectal cancer (oxaliplatin component), Ovarian cancer (cisplatin component), Testicular cancer (cisplatin component).
At a glance
| Generic name | Cisplatin / Oxaliplatin |
|---|---|
| Sponsor | Cancer Trials Ireland |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Both drugs are platinum compounds that enter cancer cells and covalently bind to DNA, creating intrastrand and interstrand cross-links. This prevents DNA unwinding and replication, leading to apoptosis. Oxaliplatin is a third-generation platinum agent with a different spectrum of activity and toxicity profile compared to cisplatin, particularly regarding neurotoxicity patterns.
Approved indications
- Colorectal cancer (oxaliplatin component)
- Ovarian cancer (cisplatin component)
- Testicular cancer (cisplatin component)
- Gastric cancer (oxaliplatin component)
Common side effects
- Nausea and vomiting
- Peripheral neuropathy
- Myelosuppression (neutropenia, thrombocytopenia)
- Nephrotoxicity
- Ototoxicity
- Anemia
- Acute oxaliplatin-specific cold dysesthesia
Key clinical trials
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer (PHASE3)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |